Dermatology practical & conceptual · 2026
Topical Metformin Compared with Clobetasol Propionate for Alopecia Areata: Clinical Outcomes from a Comparative Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saged Nashwa Mohammed, Obaid Zakaria Mahran, Fouda Ibrahim
Аннотация
INTRODUCTION: Alopecia areata (AA) is alopecia of non-scarring type caused by autoimmune mechanism that affects any area of the body with hair various patterns.
OBJECTIVES: The aim of this research was to assess the safety and effectiveness of topical metformin 30% versus clobetasol propionate 0.05% in the treatment of patchy alopecia areata.
METHODS: Thirty-four adult individuals with patchy alopecia areata participated in a randomized clinical trial and were categorized into two groups: Group I (17 participants) with metformin 30% applied twice daily for 12 weeks, and Group II (17 participants), with clobetasol propionate 0.05% administered twice daily for 12 weeks. The 5-point semiquantitative regrowth score (RGS), SALT score, and dermoscopic examination were done to evaluate the therapeutic response.3-12-0 RESULTS: At week 12, the median hair regrowth score for group I was 2, whereas for the clobetasol propionate group it was 5. There was no difference of significant importance regarding hair regrowth between the two groups, with P=0.133. Significant reductions in SALT score were observed in the two groups, and the reductions were mostly observed in Group II.
CONCLUSION: Topical metformin represents a promising and well-tolerated option in alopecia areata treatment. Although the effects of metformin 30% and clobetasol propionate 0.05% were not different, clobetasol was more effective than metformin 30% in treating localized alopecia areata.
OBJECTIVES: The aim of this research was to assess the safety and effectiveness of topical metformin 30% versus clobetasol propionate 0.05% in the treatment of patchy alopecia areata.
METHODS: Thirty-four adult individuals with patchy alopecia areata participated in a randomized clinical trial and were categorized into two groups: Group I (17 participants) with metformin 30% applied twice daily for 12 weeks, and Group II (17 participants), with clobetasol propionate 0.05% administered twice daily for 12 weeks. The 5-point semiquantitative regrowth score (RGS), SALT score, and dermoscopic examination were done to evaluate the therapeutic response.3-12-0 RESULTS: At week 12, the median hair regrowth score for group I was 2, whereas for the clobetasol propionate group it was 5. There was no difference of significant importance regarding hair regrowth between the two groups, with P=0.133. Significant reductions in SALT score were observed in the two groups, and the reductions were mostly observed in Group II.
CONCLUSION: Topical metformin represents a promising and well-tolerated option in alopecia areata treatment. Although the effects of metformin 30% and clobetasol propionate 0.05% were not different, clobetasol was more effective than metformin 30% in treating localized alopecia areata.